AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Article Link
Collect
Submit Manuscript
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Original Article

Levistilide A restrains myocardial fibrosis by targeting malate dehydrogenase 2

Ting PanΔ, Yingying ChengΔ, Yutian YanΔ, Wenjia Cao, Qingjia Jiang, Ping Li( ), Hao Zeng( )
State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing 210009, China

∆ These authors contributed equally to this work.

Show Author Information

Abstract

Myocardial fibrosis is a crucial pathological process of multiple cardiovascular diseases, yet effective therapies remain limited. Levistilide A (LA) is a bioactive constituent derived from the dried rhizome of Ligusticum chuanxiong Hort. (known as Chuanxiong in traditional Chinese medicine) with potential cardioprotective activities, but its therapeutic efficacy against myocardial fibrosis and the underlying molecular targets remain elusive. Here, we show that LA inhibits TGF-β1-induced fibroblast transformation and proliferation in vitro and alleviates myocardial fibrosis in a mouse model following myocardial infarction. By using drug affinity responsive target stability (DARTS), proteomics, and surface plasmon resonance (SPR) approaches, we identify mitochondrial malate dehydrogenase 2 (MDH2) as a putative molecular target of LA. Mechanistically, LA directly binds to MDH2 and suppresses its TGF-β1-induced phosphorylation, thereby inhibiting MDH2 enzymatic activation. This leads to the blockage of the malate-aspartate shuttle (MAS), thereby suppressing the enhanced mitochondrial oxidative phosphorylation (OXPHOS) and ultimately inhibiting fibroblast transformation and myocardial fibrosis. Therefore, our findings reveal that LA alleviates myocardial fibrosis through targeting MDH2-mediated mitochondrial metabolic reprogramming, highlighting MDH2 as a potential therapeutic target and LA as an active compound in the treatment of myocardial fibrosis.

References

【1】
【1】
 
 
Chinese Journal of Natural Medicines
Pages 1474-1485

{{item.num}}

Comments on this article

Go to comment

< Back to all reports

Review Status: {{reviewData.commendedNum}} Commended , {{reviewData.revisionRequiredNum}} Revision Required , {{reviewData.notCommendedNum}} Not Commended Under Peer Review

Review Comment

Close
Close
Cite this article:
Pan T, Cheng Y, Yan Y, et al. Levistilide A restrains myocardial fibrosis by targeting malate dehydrogenase 2. Chinese Journal of Natural Medicines, 2026, 24(12): 1474-1485. https://doi.org/10.1016/S1875-5364(26)61234-4

3

Views

0

Crossref

0

Web of Science

0

Scopus

0

CSCD

Received: 01 May 2026
Revised: 04 August 2026
Accepted: 15 September 2026
Published: 20 December 2026
© 2026, China Pharmaceutical University.